Aktuellt
SENASTE
Redeye briefly comments on the positive news that Saniona has outlicensed SAN711 to Acadia in neurological diseases. We see this as a major breakthrough for the company that should open a lot of possibilities for the company to advance and broaden its pipeline. We give our initial comment and will return after the Q3 report with a more extensive take.
LÄS MER
